Since it has the ability to target it's drug delivery to the samll intestine, it can be used to deliver drugs that can only be absorbed by the small intestine. Sturza analysts believe that European approval for Genvir will come in 3rd quarter this year. They believe that a phase II trial should start 4th quarter this year. Expertise with Polymers is the scientific base for their biotech release systems and other endeavors. Downside seems very small to me.
Time is the key.
Could be in a couple months, could take a year and half or more. Again, this one will require patience so you can't buy and 2 months later be depressed if it's dropped some. When the move comes, it will probably come very fast as they usually do. Information posted in the discussion should not be considered to be coming from Prohost Research. Prohost is an independent publication providing information on biotech companies.